rs202219343
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_006073.4(TRDN):c.1282C>T(p.Arg428Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000323 in 1,612,400 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_006073.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TRDN | NM_006073.4 | c.1282C>T | p.Arg428Ter | stop_gained | 20/41 | ENST00000334268.9 | |
TRDN | NM_001251987.2 | c.1285C>T | p.Arg429Ter | stop_gained | 20/21 | ||
TRDN | NM_001407315.1 | c.1225C>T | p.Arg409Ter | stop_gained | 19/20 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TRDN | ENST00000334268.9 | c.1282C>T | p.Arg428Ter | stop_gained | 20/41 | 1 | NM_006073.4 | A2 | |
TRDN | ENST00000662930.1 | c.1285C>T | p.Arg429Ter | stop_gained | 20/21 |
Frequencies
GnomAD3 genomes AF: 0.000237 AC: 36AN: 152024Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000129 AC: 32AN: 248510Hom.: 0 AF XY: 0.000104 AC XY: 14AN XY: 134830
GnomAD4 exome AF: 0.000331 AC: 484AN: 1460376Hom.: 1 Cov.: 33 AF XY: 0.000332 AC XY: 241AN XY: 726472
GnomAD4 genome AF: 0.000237 AC: 36AN: 152024Hom.: 0 Cov.: 33 AF XY: 0.000162 AC XY: 12AN XY: 74238
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:2
Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Feb 22, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2023 | TRDN: PM2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 05, 2022 | Has not been previously published in association with a TRDN-related disorder to our knowledge; Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a not a known mechanism of disease; This variant is associated with the following publications: (PMID: 31589614, 31980526) - |
Catecholaminergic polymorphic ventricular tachycardia 5 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 21, 2022 | - - |
Catecholaminergic polymorphic ventricular tachycardia 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 15, 2024 | This sequence change creates a premature translational stop signal (p.Arg428*) in the TRDN gene. However, it is currently unclear if variants that occur in this region of the gene cause disease. This variant is present in population databases (rs202219343, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with TRDN-related conditions. ClinVar contains an entry for this variant (Variation ID: 532333). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 14, 2023 | The p.R428* variant (also known as c.1282C>T), located in coding exon 20 of the TRDN gene, results from a C to T substitution at nucleotide position 1282. This changes the amino acid from an arginine to a stop codon within coding exon 20. This variant has been detected in the heterozygous state on exome sequencing in a case with infantile seizures and has also been detected in additional exome sequencing cohorts; however, clinical details were limited (Capalbo A et al. PLoS Genet, 2019 10;15:e1008409; Salfati EL et al. Genome Med, 2019 12;11:83; Hou YC et al. Proc Natl Acad Sci U S A, 2020 02;117:3053-3062; Park J et al. Nat Med, 2021 01;27:66-72). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. However, this alteration does not impact the predominant cardiac isoform of TRDN (NM_001256021.1; Kobayashi YM et al. J. Biol. Chem., 1999 Oct;274:28660-8). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at